GenSci134 injection for idiopathic short stature receives clinical trial approval

Changchun High & New Technology Industry Group Co., Ltd. announced its subsidiary, Changchun GeneScience Pharmaceuticals Co., Ltd. (GeneScience Pharmaceuticals), received National Medical Products Administration approval for the clinical trial application of GenSci134 Injection. The approval targets Idiopathic Short Stature (ISS) as an indication. GenSci134 Injection is a Class 1 therapeutic biologic developed by GeneScience Pharmaceuticals.

This approval is part of a broader development plan for GenSci134 Injection, which is also being explored for Growth Hormone Deficiency (GHD) in adults and children, as well as other non-GHD indications. Previous clinical trial approvals for GenSci134 Injection include adult GHD, approved on June 14, 2025, and pediatric GHD, approved on October 25, 2025.

The company anticipates that successful clinical trial progression will diversify its business structure, optimize its product portfolio, and enhance its core competitiveness. However, it cautioned investors about the inherent risks associated with pharmaceutical R&D, including long development cycles and numerous uncertain factors that could affect the clinical trial process. The company committed to timely disclosure of future developments.